QUIAPEG PHARMACEUTICALS HOLDING AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.069 SEK | -4.43% |
|
-25.49% | +4.39% |
| 02-26 | QuiaPEG Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-15 | QuiaPEG, Net Zero Infrastructure Nears Conclusion of Formal License Agreement | MT |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 44.38 | 63.1 | 86.85 | 38.51 | 30.8 | 2.729 |
| Enterprise Value (EV) 1 | 47.55 | 75.87 | 94.01 | 50.97 | 43.76 | 23.24 |
| P/E ratio | -4.17 x | -3.09 x | -2.34 x | -1.69 x | -1.15 x | -1.97 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 13.1 x | 14.1 x | 23.2 x | 4.41 x | 5.53 x | 0.62 x |
| EV / Revenue | 14.1 x | 17 x | 25.1 x | 5.84 x | 7.85 x | 5.31 x |
| EV / EBITDA | -4.25 x | -4.41 x | -3.97 x | -3.18 x | -3.13 x | -1.73 x |
| EV / FCF | -5.04 x | -5.97 x | -4.62 x | -1.84 x | -2.83 x | -0.76 x |
| FCF Yield | -19.8% | -16.8% | -21.6% | -54.4% | -35.3% | -132% |
| Price to Book | 103 x | -7.3 x | 1,241 x | 2,004 x | 12.8 x | 0.32 x |
| Nbr of stocks (in thousands) | 226 | 322 | 553 | 713 | 2,369 | 41,288 |
| Reference price 2 | 196.0 | 196.0 | 157.0 | 54.00 | 13.00 | 0.0661 |
| Announcement Date | 08/05/19 | 01/06/20 | 25/05/21 | 19/05/22 | 25/05/23 | 15/04/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3.377 | 4.466 | 3.739 | 8.73 | 5.574 | 4.374 |
| EBITDA 1 | -11.2 | -17.19 | -23.67 | -16.01 | -13.98 | -13.43 |
| EBIT 1 | -11.5 | -18.05 | -24.93 | -17.57 | -15.79 | -15.51 |
| Operating Margin | -340.6% | -404.21% | -666.86% | -201.24% | -283.35% | -354.64% |
| Earnings before Tax (EBT) 1 | -12.05 | -19.58 | -27.71 | -20 | -20.09 | -16.52 |
| Net income 1 | -12.05 | -19.58 | -27.71 | -20 | -20.09 | -16.52 |
| Net margin | -356.88% | -438.42% | -741.11% | -229.1% | -360.41% | -377.75% |
| EPS 2 | -47.00 | -63.41 | -67.07 | -31.92 | -11.34 | -0.0335 |
| Free Cash Flow 1 | -9.434 | -12.72 | -20.35 | -27.75 | -15.44 | -30.72 |
| FCF margin | -279.38% | -284.77% | -544.34% | -317.84% | -277.03% | -702.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 08/05/19 | 01/06/20 | 25/05/21 | 19/05/22 | 25/05/23 | 15/04/24 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 3.17 | 12.8 | 7.16 | 12.5 | 13 | 20.5 |
| Net Cash position 1 | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -0.2834 x | -0.7428 x | -0.3026 x | -0.7782 x | -0.9268 x | -1.527 x |
| Free Cash Flow 1 | -9.43 | -12.7 | -20.4 | -27.7 | -15.4 | -30.7 |
| ROE (net income / shareholders' equity) | -885% | 488% | 652% | -43,011% | -1,650% | -187% |
| ROA (Net income/ Total Assets) | -79% | -92% | -87.2% | -49.6% | -41.8% | -29.6% |
| Assets 1 | 15.25 | 21.29 | 31.78 | 40.35 | 48.03 | 55.73 |
| Book Value Per Share 2 | 1.900 | -26.90 | 0.1300 | 0.0300 | 1.020 | 0.2000 |
| Cash Flow per Share 2 | 10.10 | 14.30 | 15.50 | 6.260 | 1.080 | 0 |
| Capex 1 | 0.17 | 0.46 | 0.57 | 0.08 | - | - |
| Capex / Sales | 4.95% | 10.21% | 15.11% | 0.92% | - | - |
| Announcement Date | 08/05/19 | 01/06/20 | 25/05/21 | 19/05/22 | 25/05/23 | 15/04/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +4.39% | 488K | |
| +51.63% | 796B | |
| +41.51% | 628B | |
| -5.10% | 358B | |
| +19.90% | 331B | |
| +9.95% | 301B | |
| +17.66% | 244B | |
| +3.39% | 228B | |
| +10.75% | 214B | |
| +6.99% | 165B |
- Stock Market
- Equities
- QUIA Stock
- Financials QuiaPEG Pharmaceuticals Holding AB
